FRONTIER BIOTECHNOLOGIES Inc.

News

FRONTIER BIOTECHNOLOGIES Inc
Home>News>A New Drug Researched and Developed in China is Expected to be the First Long-acting Treatment against HIV infection around the world

A New Drug Researched and Developed in China is Expected to be the First Long-acting Treatment against HIV infection around the world

  • 2017-01-17  10:55:03

On November 23, 2016, the new generation of anti-HIV drug (HIV fusion inhibitor - Albuvirtide) debuted. Albuvirtide was independently researched and developed by Chinese scientists with the support of national major scientific and technological project. NDA was accepted by SFDA. With the guidance of the green channel , Albuvirtide was given special consideration for application process. . Most likely, it will become the first long-acting anti-HIV injection in the world.


The long-acting injection can provide more clinical benefits to people living with HIV than oral medication. it is the leading trend of R&D for new anti-HIV drug worldwide. Albuvirtide utilize a unique mechanism to prevent the virus from entering the target cells. It can block the virus replication during initial cycle infection. A member of the AIDS clinical working team of China National Health and Family Planning Commission introduced this medicine, “the drug administration departments of any country, including FDA and other authorities, have not approved any long-acting anti-HIV drug. Albuvirtide is expected to be the first long-acting anti-HIV in the world”.


Innovative solutions to promote human health